Craig-Hallum lowered the firm’s price target on MiMedx (MDXG) to $6 from $7 and keeps a Buy rating on the shares. The firm cites MiMedx’s Q1 results and guidance, which came in below the Street as Wound pressures were more severe than expected following reimbursement changes and claims disruptions.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG: